SeeThruEquity issued a company update and price target of $4.30 on shares of Apricus Biosciences, Inc.’s (NASDAQ: APRI) stock. The analyst noted that the company has several upcoming catalysts, including the FDA decision for its Vitaros™ New Drug Application (NDA) resubmission. The company has already received its PDUFA date, which is February 17, 2018. If approved, Vitaros™ could be commercialized in the multi-billion-dollar erectile dysfunction (ED) market by the end of 2018.
For more information, visit www.Apricusbio.com
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud`s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com